Barr Laboratories, Inc., has recalled a generic stimulant


The company is voluntarily recalling its bottles of 100-count, 20-milligram tablets of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate -- lot No. 311756, according to the U.S. Food and Drug Administration.

The product, typically prescribed for attention deficit and hyperactivity disorder, as well as narcolepsy, is being recalled because the affected lot may contain some tablets with doses stronger than indicated on the label.

Potentially adverse reactions to a super-potent dose include heart, neurologic, psychiatric and gastrointestinal reactions. Those can include palpitations, hypertension, headache, tremor, dizziness, blurred vision, sweating, insomnia, anxiety and nausea, the FDA said in a press release Friday.

The product is an oval, peach-colored tablet, with "b/973" on one side and "2/0" on the other. Barr distributed the affected lot between June 11-16 of this year. Only lot No. 311756 is affected by the recall. No adverse incidents have been reported.

Customers who have the tablets should stop using it and return it to their pharmacist. For more information call 888-742-5578.


Use the comment form below to begin a discussion about this content.

Sign in to comment

Click here to sign in